The Clinic That Issued the Prescription Did Not Exist: Ruti Aga's Six-Year Ban Was a Documents Case, Not a Drug Case

The clinic that issued the prescription did not exist. The person who signed it was not on any medical register, and he was a member of Ruti Aga's own family. The pad the prescription was written on was said to belong to a former workplace — and that clinic explicitly denied any link to it. The Athletics Integrity Unit (AIU) released its statement on a Thursday. I read it three times, because the first pass left me convinced I had misread a line.

The arithmetic of the six-year ban breaks into two and four. Two years for a positive sample, four years for the piece of paper manufactured to explain that sample. Ruti Aga, 32, Ethiopia, winner of the 2026 Tokyo Marathon. Her name has now gone into the separate file I have been keeping for some years — the cases where the substance was secondary and the document was the story. Let me show you the receipts before I show you the conclusion.

Context: what the record keeps, and what the question keeps

The AIU statement does not give her personal best. My own ledger has Berlin 2026, second in 2:18:34 behind Gladys Cherono; Tokyo 2026, the title in 2:20:40; and three second-place finishes at World Marathon Majors across her career. Those numbers come from external records, not from the statement, and I am putting them on the table because without them it is hard to grasp the calibre of athlete involved. The 2:18-to-2:20 band is where you can win a Major and where an Olympic medal is a live conversation — and where you cannot win every time.

The race that produced the sample was a half marathon in China in March, and Aga won it. The statement carries no name for the race, no time, no field depth. There is no data here. That is the finding — and it is the first honest sentence in this whole story. What is recorded is only this: the race was won, the sample that followed was positive, and she had been provisionally suspended since 10 September. The statement gives neither the year of the March race nor the year the ban ends. When an official document leaves dates half-open, the first job is to treat what is written as written and move what is missing into the column marked estimates.

Core: the substance was misclassified, and that is the case's biggest technical turn

Media reports described methylprednisolone as a "prohibited steroid" and stated that WADA classes it as performance-enhancing. That classification is wrong. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid under S1. And the S9 condition is specific: it is prohibited in-competition only, and only by injection, oral or rectal route. In practice that means a therapeutic knee injection given out-of-competition is entirely legal. It becomes a violation the moment residues are detected in-competition.

One correction and the whole case shifts position. This was not a steroid-use case. It was a route-and-timing case. And timing here is no minor detail — a road race's in-competition testing window opens at 23:59 the day before the race. An injection given days earlier is caught if anything is left in the system. Had Aga possessed a genuine record of the knee treatment, her defence would have stood on solid technical ground: the drug, the route, the date, the clearance calculation.

She did not have that record. She had a prescription. And all three legs of the prescription broke in different places.

Core: what two plus four actually tells us

Anyone who reads sanction numbers as headlines will find this addition useless. But 2 + 4 = 6 is an argument here, and the panel wrote it itself. Two years for the presence violation — consistent with the category the Code calls a Specified Substance, where intent unproven can soften the period. Four years for tampering — the Code's standard sanction, with no leniency applied.

The most important information in that sum is what does not appear in it: the panel rejected the no-significant-fault mitigation. Had that mitigation been accepted, the presence sanction could have fallen below two years. Fabricating a document is itself circumstantial evidence of concealment intent, and this is where the case looks tangled. The very act treated as evidence of intent to conceal did not escalate the presence sanction; the panel kept the two accounts separate. Technically clean, humanly brutal — the athlete paid interest on both accounts, and neither account worked in her favour.

Reading the 10 September backdating as relief is the most common error. Provisional suspension time counts against the ban; that is procedure, not discount. Nothing real came back to the athlete. The spreadsheet was clean. The story was not.

Core: the counterfactual nobody wrote

I am tired of the question these cases always attract: "Is she guilty?" The better question is this — had she taken the same drug and kept the right paperwork, would there be a case at all?

The answer is close to no. Two doors were open. One, a therapeutic use exemption, which requires documented treatment of the knee injury and an application filed before competition. Two, even without a TUE, managing route and washout so that nothing remained in-competition. Neither leaves a trace in the record. What leaves a trace is a prescription that was manufactured.

This is where my 2026 work comes back to me. In the pandemic months, when live data stopped, I wrote a scraper against AFI and state-meet result PDFs — 1,400 documents, 2026 to 2026. That exercise taught me something that applies directly here: the weakest link in any sports system is never the result, it is the document. Anyone can produce a result. Producing a document requires a structure that can connect hospital, registration, pad and file to one another. Where that structure is missing, prescriptions get written.

Core: China's label races, appearance fees, and the AIU's richest hunting ground

The statement does not name the March half marathon. The logic is straightforward: if the AIU tested there, it was a World Athletics Label road race with an elite women's field and testing present. And that reveals an economy I have been writing about for a while.

For East African marathoners, the Chinese road circuit is a tier where appearance fees are good, the competition is lighter than a Major, and the physical toll is lower. In the months between Majors it is the easiest income available. That same tier is now the AIU's highest-yield testing zone. The race an athlete selects for income is the race an agency selects for surveillance. Two economies are colliding on the same course, and in a collision the runner always falls first, never the agent.

Core: the knee is the real root, and it is a systemic signal, not an individual one

The statement says the methylprednisolone was for a knee injury. Chronic knee pathology is no exception among marathoners — it is the sport's most common load-bearing failure. That is exactly why the medical story is mechanically plausible. And exactly why the forged prescription is so destructive: someone with a genuine treatment record defends herself with genuine paper.

The question does not end there. It becomes: why was there no credentialed team physician around her. The prescription was written by a family member with no medical registration, who said he had used a pad from a former workplace. This is not a filing error. It is the signature of an athlete operating without institutional medical support. No TUE infrastructure, nobody tracking washout, and when the crisis arrived the easiest visible route was to make paper.

Note also that the four-year sanction came from an interview, not a document alone — meaning it rests on statements given under questioning. When an athlete's answers are recorded in a language other than her own, in someone else's words, that is always contested ground. We do not know what language the interview used, who interpreted, or who chose which sentence. That information is not in the statement. I went looking for a trend and found a hole.

Contrarian: the proportionality of six years, and the deception of the word "steroid"

Start with the word that placed this story in the wrong category worldwide. Call it a steroid and the reader's mind goes to the anabolic cases of 2026-16, to muscle-building. This case belongs to none of that. This is an anti-inflammatory with no proven endurance benefit, legally usable out-of-competition, where a violation arises only from an error of timing and route. When media erases that distinction, proportionality becomes impossible to read — and when proportionality is unreadable, people conclude either that the punishment is excessive or that the athlete is a cheat. Both are wrong.

Next, the assumption that six years was given for the drug. It was not. Two years were given for the drug, four for the lie built to cover it. Anyone presenting this as "six years for a glucocorticoid" weakens their own argument. The real question is whether four years is the right price for manufacturing a document, when the same four years attach to substances that directly enhance performance. The Code has sent a clear message, and the message is not about pharmacology: lying to the system is treated as a graver offence than deceiving it. That logic is coherent, because verification is the foundation of the entire anti-doping structure. It is also merciless to an athlete who has already served two years for the original violation.

Third, the charge that cannot be dismissed from the AIU's numbers and cannot be proven from them either. Tampering charges recur in East African road-running cases. That can be read two ways: as evidence of the agency's rigour, or as evidence that where no credentialed medical support exists, athletes will attempt to make their own paper and get caught — while an athlete using the same drug with a team doctor and a lawyer goes paperwork-clean through a TUE. I am not concluding that the rules are wrong. I am concluding that the rules catch those who lack the infrastructure to live with them. That is not enforcement failure. It is the enforcement frontier, and that frontier moves with money and institutions.

Core: what survives in the record book

This is the part the statement is silent on and the coverage never asked about. The violation is anchored to the March race. Absent a finding of earlier use, results before that date are not automatically annulled. The 2026 Tokyo title, the 2026 Berlin silver, the three Major podiums — they stay in the ledger where they were. At the same time, the March result and its prize money are very likely voided, because standard AIU practice disqualifies the competition at which the sample was collected, even where the statement does not spell it out.

The record now splits in two, and the split is uncomfortable. On one side, an athlete who ran 2:18 and won a Major. On the other, an athlete whose name is attached to documentary fraud. Both belong to the same person. My job is not to pick one; it is to hold both in a single table, and the table says what the record book always says — it measures time, and time never tells you which document stood behind it.

Contrarian: a return at 38, and a depth that does not rest on one name

Six years at 32 means a return at roughly 38. Against Ethiopian women's marathon depth, that return would be on paper only. When a country has multiple 2:14-2:16 performers, a 2:18 runner is not automatically selectable — and a 38-year-old with a doping record is certainly not. It follows that her removal does not alter Ethiopia's medal capacity by any measurable margin. That sounds cold, but the ledger is cold: three Major second places are commercial-tier results, not championship conversions.

Framing this as a blow to Ethiopian marathon running is therefore dishonest with the numbers. What took the blow was her earning power and her name, not the country's depth. And this is where I have to guard against my own habit — I could easily have declared this case proof of systemic failure, because the argument sounds good. The evidence says only that one athlete had no institutional medical support around her, and that she made paper. The rest of the story is not yet on file. Every model is an argument. This one argues for patience.

Takeaway: what to watch next

Three things in the coming weeks. First, the CAS appeal window — typically around 21 days from the reasoned decision. The forgery finding rests on documents and is hard to overturn, but proportionality can be appealed, and it will be worth watching whether the four-year tampering limb is challenged. Second, formal confirmation that the March result and prize money are voided — unstated in the statement, and what goes unstated tends to surface later. Third, and most important, the pipeline. When several athletes in one training cluster share an informal medical network, one case surfacing does not mean the others do not exist. It means they have not yet entered document review.

That is the real lesson. The next anti-doping fight will not be fought in the sample; it will be fought in the prescription. The day agencies can connect clinic, registration and pad records as quickly as they connect a urine bottle, forged prescriptions will stop being written. Until then the question stands: who does the sport punish — the drug with no proven benefit, or the lie with a visible one?